azomycin has been researched along with Retinopathy of Prematurity in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Al-Shabrawey, M; Bartoli, M; Behzadian, MA; Caldwell, RB; Caldwell, RW; El-Remessy, AB; Istanboli, M; Labazi, M; Marcus, DM | 1 |
1 other study(ies) available for azomycin and Retinopathy of Prematurity
Article | Year |
---|---|
HMG-CoA reductase inhibitors (statin) prevents retinal neovascularization in a model of oxygen-induced retinopathy.
Topics: Animals; Blotting, Western; Capillaries; Disease Models, Animal; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Indoles; Infant, Newborn; Intercellular Adhesion Molecule-1; Lipid Peroxidation; Mice; Nitroimidazoles; Oxygen; Phosphorylation; Retinal Neovascularization; Retinal Vessels; Retinopathy of Prematurity; STAT3 Transcription Factor; Superoxides; Vascular Endothelial Growth Factor A | 2009 |